NasdaqGS - Delayed Quote • USD
Cytokinetics, Incorporated (CYTK)
At close: April 23 at 4:00 PM EDT
Pre-Market: 8:57 AM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 15 | 15 | 16 | 15 |
| Avg. Estimate | -1.14 | -1.12 | -4.45 | -3.29 |
| Low Estimate | -1.35 | -1.36 | -5.42 | -5 |
| High Estimate | -0.89 | -0.82 | -3.43 | -1.53 |
| Year Ago EPS | -1.38 | -1.34 | -5.45 | -4.45 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 13 | 13 | 15 | 15 |
| Avg. Estimate | 900k | 880k | 6.41M | 144.98M |
| Low Estimate | -- | -- | -- | 5M |
| High Estimate | 1.3M | 1.3M | 45.43M | 394.65M |
| Year Ago Sales | 4.61M | 5.8M | 7.53M | 6.41M |
| Sales Growth (year/est) | -80.50% | -84.80% | -14.90% | 2,161.80% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -1.2 | -1.15 | -0.74 | -0.97 |
| EPS Actual | -1.38 | -1.34 | -1.35 | -1.38 |
| Difference | -0.18 | -0.19 | -0.61 | -0.41 |
| Surprise % | -15.00% | -16.50% | -82.40% | -42.30% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -1.14 | -1.12 | -4.45 | -3.29 |
| 7 Days Ago | -1.14 | -1.12 | -4.45 | -3.29 |
| 30 Days Ago | -1.14 | -1.12 | -4.46 | -3.31 |
| 60 Days Ago | -1 | -1.02 | -4.53 | -3.3 |
| 90 Days Ago | -1 | -1.02 | -4.53 | -3.3 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 1 | 1 | 1 |
| Up Last 30 Days | 2 | 2 | 2 | 2 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | CYTK | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 17.40% | -- | -- | 0.30% |
| Next Qtr. | 16.40% | -- | -- | 9.80% |
| Current Year | 18.30% | -- | -- | 4.50% |
| Next Year | 26.10% | -- | -- | 13.40% |
| Next 5 Years (per annum) | 15.00% | -- | -- | 11.06% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Needham: Buy to Buy | 4/9/2024 |
| Reiterates | Truist Securities: Buy to Buy | 4/8/2024 |
| Maintains | JP Morgan: Overweight to Overweight | 3/7/2024 |
| Maintains | Mizuho: Buy to Buy | 3/6/2024 |
| Reiterates | Oppenheimer: Outperform to Outperform | 3/4/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 2/28/2024 |
Related Tickers
BBIO BridgeBio Pharma, Inc.
25.46
+1.56%
DAWN Day One Biopharmaceuticals, Inc.
16.64
+8.19%
IMVT Immunovant, Inc.
28.61
-0.45%
MDGL Madrigal Pharmaceuticals, Inc.
218.38
+2.29%
BPMC Blueprint Medicines Corporation
92.29
+1.85%
BHVN Biohaven Ltd.
39.61
+3.34%
JANX Janux Therapeutics, Inc.
49.78
+1.84%
CLRB Cellectar Biosciences, Inc.
3.1100
-2.51%
APLS Apellis Pharmaceuticals, Inc.
48.72
+2.27%
CRNX Crinetics Pharmaceuticals, Inc.
44.22
+1.80%